Jul. 9 at 12:20 PM
$IMRX On July 9, 2025, the United States Patent and Trademark Office (USPTO) granted Immuneering Corporation a composition of matter patent for atebimetinib (IMM-1-104), an oral, once-daily MEK inhibitor designed to treat MAPK pathway-driven tumors, such as pancreatic cancer. The patent, with a term expected to expire in August 2042 (potentially extendable upon regulatory approval), strengthens Immuneering’s intellectual property portfolio, which also includes pending applications for compounds, pharmaceutical compositions, and methods of use expected to extend protection into 2044. Atebimetinib, currently in a Phase 2a trial, has shown promising results, with a 94% overall survival rate at six months in first-line pancreatic cancer patients when combined with modified gemcitabine/nab-paclitaxel (mGnP), alongside a favorable tolerability profile. This patent validates the novelty of Immuneering’s approach and supports its efforts to advance atebimetinib toward a pivotal trial in 2026.
